608720login-checkPatient Voice Needed: Access to post-transplant testing may be impacted |
In November of 2022 MolDX (a program charged with developing CMS coverage policies for molecular diagnostic tests) and Noridian (the Medicare Administrative Contractor for CareDx and other labs located in California) held advisory meetings to review the clinical evidence for post-transplant diagnostics products. This includes AlloSure and AlloMap.
These meetings may inform coverage for molecular diagnostic testing for transplant patients and could impact access to these tests.
CareDx recognizes that the patient voice is key when making these decisions as they add personal stories that make the products’ impact more concrete and real.
This is where you come in! We need your help to share your AlloSure or AlloMap story, and support for continued access to post-transplant care options through the below form. While doing so in your own words is best, we created a template which we hope would be helpful and allows you to send your letter of support directly to the agencies responsible for the review.
Send your letter of support here.
Thank you for your advocacy for the transplant community.
608720login-checkPatient Voice Needed: Access to post-transplant testing may be impacted |